Tuberculosis Diagnostics Market Size is estimated to exhibit a substantial CAGR from 2022 to 2028, owing to the soaring demand for different types of tests comprising TB blood tests and TB skin tests. While a positive test merely indicates infection with TB bacteria, it does not confirm if a person has progressed to TB disease or has latent TB infection. This factor is propelling the demand for other tests such as sample of sputum and chest x-ray.
By testing type, nucleic acid testing segment is set to account for a lucrative revenue in the market share through 2028. This rise is chiefly attributed to the increasing advocation of these procedures by several regulators. For instance, according to the recommendations of the CDC, NAA testing should be treated as a priority test in the U.S. and all public health TB programs and clinicians should get access to molecular tests to aid in TB diagnosis. Additionally, it has also recommended that NAA testing should be adopted as the standard practice for TB suspects. These factors are expected to drive segment growth during the forecast period.
Based on end use, the market value is predicted to register commendable growth from the hospitals segment during the forecast period. This is on account of the rising demand for diagnostic procedures in hospital settings and the increasing pervasiveness of MDR (multi-drug resistant) tuberculosis. The segment expansion is further led by the escalating development of healthcare infrastructure and increasing investments by numerous governments for reducing the burden of tuberculosis.
Asia Pacific tuberculosis diagnostics market share is anticipated to record remarkable expansion through 2028. This growth is attributed to the increasing number of innovations in the field of TB diagnostics. Numerous products on the market range from laboratory-based molecular diagnostics to AI (artificial intelligence) for CXR (chest x-ray) interpretation. In 2021, analysis of the results of studies of Lunit from South Korea and Qure.ai from India contributed to the recommendations of the World Health Organization for CAD (computer-aided detection) of CXRs.
Major companies in the market comprise BioMerieux SA, AdvaCare Pharma, Hologic Corporation, Abbott Laboratories, Roche AG, Qiagen, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Cepheid, Hain Lifescience. These participants are focusing on acquisitions, mergers, product launches, partnerships, and collaborations for securing a competitive edge in the market.
For instance, in July 2021, Roche announced that the cobas MTB-RIF/INH and cobas MTB tests for deployment on the cobas 6800/8800 systems have been included as part of the updated WHO policy guidelines on NAATs for the detection of drug-resistant TB and tuberculosis. The new guidance extends the number of rapid molecular tests that are available to national TB programs in high-burden countries, in turn allowing multi-partner diagnostic approaches that can benefit communities and patients.
In the pandemic period, tuberculosis and COVID-19 are projected to pose a dual threat in light of the prevalent poverty and social inequities. The SARS-CoV-2 outbreak has led to a mass setback to progress in reaching tuberculosis targets, making it imperative to leverage innovative models for the improvement of tuberculosis control and care. As per statistics, around 1 million people have found it difficult to get diagnosed with tuberculosis during the pandemic period. This is driving the demand for numerous tuberculosis diagnostic tests and procedures across various regions.
Market, by Test Type
Market, by End-use
The above information is provided for the following regions and countries: